We are live on ! Find out more
BBLG

Bone Biologics
BBLG

6 hedge funds and large institutions have $576K invested in Bone Biologics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

3.43% less ownership

Funds ownership: 16.36% → 12.93% (-3.4%)

11% less capital invested

Capital invested by funds: $647K → $576K (-$70.9K)

14% less funds holding

Funds holding: 7 → 6 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$1.46M
2
WAM
Warberg Asset Management
Illinois
+$142K
3
VF
Virtu Financial
New York
+$86.9K
4
TRCT
Tower Research Capital (TRC)
New York
+$31.4K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$214K
2
MWA
MFA Wealth Advisors
Pennsylvania
-$25K
3
UBS Group
UBS Group
Switzerland
-$11.3K
4
Millennium Management
Millennium Management
New York
-$5K

BBLG Hedge Fund Activity: Q2 2023 in Review

6 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2023, worth a combined $576K — down 11% from $647K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BBLG and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was Walleye Capital, adding an estimated $1.46M. The largest seller was Sabby Management, cutting an estimated $214K.

  • 6 institutional investors held Bone Biologics (BBLG) as of Q2 2023, down from 7 in Q1 2023.
  • Funds reported $576K of Bone Biologics stock for Q2 2023, down 11% quarter-over-quarter.
  • 2 funds opened new Bone Biologics positions in Q2 2023 and 3 closed out, a net change of -1 holder.
  • The largest Bone Biologics buyer in Q2 2023 was Walleye Capital, an estimated $1.46M added.
  • The largest Bone Biologics seller in Q2 2023 was Sabby Management, an estimated $214K sold.

Based on aggregated 13F filings for Q2 2023.